Drug intelligence / Profile preview

eribulin + evexomostat

Development stage: Unknown
Lead developer: SynDevRx
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

Eribulin + evexomostat is an investigational combination therapy being studied for the treatment of metastatic triple-negative breast cancer (TNBC) in patients with metabolic dysfunction such as obesity or insulin resistance. Eribulin is a microtubule dynamics inhibitor and standard chemotherapy agent approved for metastatic breast cancer. Evexomostat (SDX-7320) is a novel polymer–drug conjugate of a methionine aminopeptidase 2 (MetAP2) inhibitor designed to inhibit tumor growth and metastasis while also improving metabolic disorders by restoring insulin sensitivity. The combination aims to address both the oncologic and metabolic aspects of TNBC progression in this patient population[1][3][4][5][6][9][10].

Other names: SDX-7320SDX7320SDX 7320evexomostateribulin mesylate

Targets

METAP2 (Methionine aminopeptidase 2)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on eribulin + evexomostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eribulin + evexomostat.

Explore the full profile